You are here: Scientific Experts > Denmark > University of Copenhagen > Ejlertsen > Bent Ejlertsen
Affiliation: University of Copenhagen
Strasser Weippl K, Horick N, Smith I, O Shaughnessy J, Ejlertsen B, Boyle F, et al. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015;17:56 pubmed publisher
..The event rates shown for subpopulations of HER2+ BC patients suggest that in resource-constrained environments patients with HER2+â€‰HR- early BC should be prioritized for consideration of adjuvant anti-HER2 therapy. ..
Strasser Weippl K, Horick N, Smith I, O Shaughnessy J, Ejlertsen B, Boyle F, et al. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 2016;56:85-92 pubmed publisher
..NNT in HER2+ HR- patients are in range with those reported from up-front adjuvant trastuzumab trials. ..